AbbVie will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time. A live audio webcast ...

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, today announced a $62 million Series A financing. The financing was led by founding investor Versant Ventures ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

This was the stock's third consecutive day of losses.

AbbVie Inc (ABBV) stock saw a decline, ending the day at $179.53 which represents a decrease of $-0.57 or -0.32% from the prior close of $180.1. The stock opened at $179.63 and touched a low of ...

Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on AbbVie (ABBV – Research Report) yesterday and set a price target of ...

This was the stock's second consecutive day of losses.

Health care stocks trended downward for most of 2024, significantly underperforming broader stock indexes. Over the past year, the S&P 500 Health Care index rose by only 0.